Abstract
Therapeutic hypothermia improves neurodevelopmental outcome following perinatal asphyxial encephalopathy and has now become 'standard of care' in industrialised countries. However, none of the cooling trials so far have been conducted in developing countries, where approximately one million asphyxial deaths occur every year. Use of therapeutic hypothermia in such settings raises several clinical, pragmatic and ethical issues. We suggest that rigorous clinical trials of cooling are required to ensure that a safe and effective neuroprotective therapy demonstrated in high resource settings does not become an unsafe and ineffective practice in low resource settings.
| Original language | English (UK) |
|---|---|
| Pages (from-to) | 79-81 |
| Number of pages | 3 |
| Journal | International Health |
| Volume | 2 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Jun 2010 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Hypoxic ischemic encephalopathy
- Intrapartum-related neonatal deaths
- Low-income countries
- Newborn
- Therapeutic hypothermia
Fingerprint
Dive into the research topics of 'Global application of therapeutic hypothermia to treat perinatal asphyxial encephalopathy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver